ReviewGastroenterology clinics of North America2016
Current Perspectives on Gastric Cancer.
Review in Gastroenterology clinics of North America, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Trends and hot spots in research on the prognostic value of gastric cancer biomarkers in the context of the Lauren classification: a bibliometric analysis.Frontiers in medicine · 2025Pooled it
- Vitamin D-The Nutritional Status of Post-Gastrectomy Gastric Cancer Patients-Systematic Review.Nutrients · 2022Pooled it
- Statins Are Associated with Improved Survival of Patients with Gastric Cancer: A Systematic Review and Meta-Analysis.International journal of clinical practice · 2022Pooled it
- The effect of using simethicone with or without N-acetylcysteine before gastroscopy: A meta-analysis and systemic review.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology AssociationPooled it
- Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- Evaluation of the Anticancer Effects of DODP on Gene Expression and Oxidative Stress in Gastric Cancer: An Integrated Docking, Bioinformatics, and Experimental Approach.Life (Basel, Switzerland) · 2026Article
- Targetable pathways for drug repurposing in gastric cancer.World journal of gastroenterology · 2025Review
- Periodontal Status and Gingival Crevicular FluidJournal of clinical medicine · 2025Article
- Tumor budding in gastric adenocarcinoma: prognostic value and association with clinicopathological markers.Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery · 2025Article
- UBE2R2-AS1, as a prognostic marker of gastric cancer, promotes the malignant phenotype of gastric cancer cells.Histology and histopathology · 2024Article
- Real-world effectiveness of a new powered stapling system with gripping surface technology on the intraoperative clinical and economic outcomes of gastrectomy for gastric cancer.Cost effectiveness and resource allocation : C/E · 2024Article
- Investigating the relationship between Epstein-Barr virus infection and gastric cancer: A systematic review and meta-analysis.Health science reports · 2024Review
- Molecular mechanisms underlying the action of carcinogens in gastric cancer with a glimpse into targeted therapy.Cellular oncology (Dordrecht, Netherlands) · 2022Review
- Helicobacter pylori Modulated Host Immunity in Gastric Cancer Patients With S-1 Adjuvant Chemotherapy.Journal of the National Cancer Institute · 2022Article
- The immune microenvironment in gastric adenocarcinoma.Nature reviews. Gastroenterology & hepatology · 2022Review
- MiR-139-5p Inhibits the Development of Gastric Cancer through Targeting TPD52.Journal of healthcare engineering · 2022Article
- Reducing tumor invasiveness by ramucirumab and TGF-β receptor kinase inhibitor in a diffuse-type gastric cancer patient-derived cell model.Cancer medicine · 2021Article
- B7 homologue 3 as a prognostic biomarker and potential therapeutic target in gastrointestinal tumors.World journal of gastrointestinal oncology · 2021Review
- Circular RNA hsa_circ_0001874 is an indicator for gastric cancer.Journal of clinical laboratory analysis · 2021Article
- Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Gastric cancer (GC) is third leading cause of cancer-related death. Only 28.3% of new GC cases survive more than 5 years. Although incidence has declined in the United States, an increase is estimated for 2016. Risk factors include sex (risk is higher in men), Helicobacter pylori infection, heredity, and lifestyle. GC is usually diagnosed between the ages of 60-80 years. Prognosis of GC is largely dependent on the tumor stage at diagnosis and classification as intestinal or diffuse type; diffuse-type GC has worse prognosis. Chemoprevention has been shown to decrease risk, but is currently not used clinically.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.